active psoriatic arthritis
Bristol Myers Squibb’s New Drug Application for mezigdomide accepted by FDA
Mezigdomide improves progression-free survival in patients with relapsed or refractory multiple myeloma
Bristol Myers Squibb and SystImmune announce phase 3 results for antibody-drug conjugate
The drug showed improvements in overall survival and progression-free survival in two cancers
Bristol Myers Squibb evolves and expands multiple myeloma programme
Created in 2016, the Standing in the Gaap programme aims to advance more equitable care
BMS’ Opdivo gets expanded FDA and EU approval for Hodgkin lymphoma
This type of cancer is the most common one diagnosed in teenagers
Bristol Myers Squibb’s Sotyktu approved by US FDA for psoriatic arthritis
Sotyktu is the first TYK2 inhibitor approved for active psoriatic arthritis
BMS announces affordable drug price agreement with US government
The company will provide Eliquis, its oral blood thinner, free of charge to Medicaid
BMS granted FDA priority review for Breyanzi in marginal zone lymphoma
The disease accounts for approximately 7% of all non-Hodgkin lymphoma cases
BMS and Bain Capital launch new company to develop immunology therapies
The newly formed company has in-licensed five investigational immunology drugs from BMS
BMS and BioNTech partner on solid tumour candidate in deal worth over $11bn
BioNTech’s BNT327 is being evaluated in multiple clinical trials, including phase 3 studies in first-line lung cancer
Bristol Myers Squibb’s perioperative Opdivo regimen granted EC approval in NSCLC
Up to 55% of patients with non-metastatic NSCLC develop recurrence despite curative resection
Bristol Myers Squibb’s injectable Opdivo formulation granted MHRA for solid tumours
The new formulation reduces administration time from 30-to-60 minutes to three-to-five minutes
BMS receives NICE recommendation for immunotherapy combination in colorectal cancer
Approximately 44,000 people are diagnosed with colorectal cancer in the UK every year